Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | CASP7 | P55210 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL72801 | 0.82 | DCPS (0.64) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL29583288 | 0.82 | DCPS (0.64) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL841779 | 0.71 | HSD17B10 (0.70) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL29809559 | 0.71 | HSD17B10 (0.70) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL1064424 | 0.71 | QTRT1 (0.49) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL1675370 | 0.71 | CLK1 (0.66) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL14828514 | 0.69 | QTRT1 (0.51) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL71734 | 0.69 | CLK1 (0.51) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL1008808 | 0.69 | ADORA3 (0.51) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL1059574 | 0.69 | DHFR (0.53) | KDM4EALDH1A1HPGDHSD17B10GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069373-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100056501-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
| US-7655647-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20100009966-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090170831-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-07-02 | — | — | US | disclosed |
| US-7498324-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080221087-A1 | Substituted lactams as inhibitors of abeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-09-11 | — | — | US | disclosed |
| US-7390802-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-06-24 | — | — | US | disclosed |
| US-7276495-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20060211679-A1 | Substituted lactams as inhibitors of Abeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-09-21 | — | — | US | disclosed |
| US-7001901-B2 | Tetrazolylpropionamides as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20050234039-A1 | Prevent forming deposits of amyloid protein on nervous systems; Alzheimer's disease; Down syndrome | HAN QI | 2005-10-20 | — | — | US | disclosed |
| US-6900199-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040138201-A1 | Substituted lactams as inhibitors of Abeta protein production | HAN QI (US) | 2004-07-15 | — | — | US | disclosed |
| US-20040082568-A1 | Central nervous system disorders; Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-29 | — | — | US | disclosed |
| US-6632812-B2 | Alzheimer's disease; Down syndrom | DUPONT PHARMACEUTICALS COMPANY | 2003-10-14 | — | — | US | disclosed |
| EP-1289966-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020025955-A1 | Substituted lactams as inhibitors of A beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-28 | — | — | US | disclosed |
| WO-2001077086-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF Aβ PROTEIN PRODUCTION | DUPONT PHARMACEUTICALS COMPANY (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221087-A1 | Substituted lactams as inhibitors of abeta protein production | BACE1, APP, APH1A | KDM4E 4239/4885ALDH1A1 3896/4885HPGD 1884/4885 |
| US-20020025955-A1 | Substituted lactams as inhibitors of A beta protein production | BACE1, APP, APH1A | KDM4E 4310/4885ALDH1A1 3160/4885HPGD 2020/4885 |
| US-20100009966-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | KDM4E 4239/4885ALDH1A1 3896/4885HPGD 1884/4885 |
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | KDM4E 4239/4885ALDH1A1 3896/4885HPGD 1884/4885 |
| US-20040082568-A1 | Central nervous system disorders; Alzheimer's disease | APP, APBA1, DNPEP | KDM4E 3827/4885ALDH1A1 1424/4885HPGD 2521/4885 |
| US-20090170831-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | KDM4E 3998/4885ALDH1A1 3909/4885HPGD 2240/4885 |
| US-20040138201-A1 | Substituted lactams as inhibitors of Abeta protein production | BACE1, APP, APH1A | KDM4E 4301/4885ALDH1A1 3436/4885HPGD 1981/4885 |
| US-20060211679-A1 | Substituted lactams as inhibitors of Abeta protein production | BACE1, APP, APH1A | KDM4E 4239/4885ALDH1A1 3896/4885HPGD 1884/4885 |
| US-20100069373-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BACE1, APP, BACE2 | KDM4E 4231/4885ALDH1A1 3509/4885HPGD 1850/4885 |
| US-20100056501-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | KDM4E 4239/4885ALDH1A1 3896/4885HPGD 1884/4885 |
| US-20050234039-A1 | Prevent forming deposits of amyloid protein on nervous systems; Alzheimer's disease; Down syndrome | APP, BACE1, PSEN1 | KDM4E 4703/4885ALDH1A1 4175/4885HPGD 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.